Sanara MedTech (SMTI) Q3 2024 earnings summary

Executive summary

• Achieved twelfth consecutive record net revenue quarter at $21.7 million in Q3 2024, a 35% year-over-year increase, driven by expanded distribution and product sales.

• Adjusted EBITDA improved to $0.8 million in Q3 2024 from $0.3 million in Q3 2023.

• Net loss for Q3 2024 was $2.9 million, up from $1.1 million in Q3 2023, mainly due to higher SG&A, interest, and earnout liability expenses.

• Continued investment in THP, with commercial launch targeted for mid-2025 and estimated spend of $5–10 million through launch.

• All revenue and gross profit in the period were generated by the surgical segment; THP is pre-revenue.

Financial highlights

• Q3 2024 net revenue: $21.7 million (+35% YoY); gross profit: $19.7 million (+38% YoY); gross margin: 91%.

• Q3 2024 net loss: $2.9 million (vs. $1.1 million in Q3 2023); SG&A expenses: $19.0 million (vs. $13.9 million); interest expense: $0.9 million (vs. $0.2 million).

• Cash balance at quarter-end: $16.3 million, up from $6.2 million in Q2 2024 and $5.1 million at year-end 2023.

• Diluted net loss per share was $0.34, compared to $0.13 in Q3 2023.

• Total assets increased to $88.5 million; total liabilities rose to $49.1 million at quarter-end.

Outlook and guidance

• THP commercial launch planned for mid-2025, with pilot programs in the first half of 2025 and continued investment through launch.

• No immediate profitability expected for THP at launch; ramp-up period anticipated.

• Management focused on growth, market expansion, and partnerships, including new specialties and facilities.

• Expectation of continued improvement in operating results and adjusted EBITDA.

• Commercial launch of new cryotherapy device expected in 2025, with reimbursement code effective July 2024.